Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06173713

Emphasys Radiostereometric Analysis

This study is designed as a prospective, multi-centre, non-randomized, non-controlled study. This study does not limit the procedures involved in the treatment of the subject as long as the protocol specified products are utilized.

The primary objective is to establish the mean superior cup migration of the Emphasys Shell and the mean inferior stem migration of the Emphasys Stem using model-based RSA over the first two years post-implantation. Additionally, the data from this study will be compared to historical Pinnacle Acetabular Shell data obtained in study DSJ_2018_02.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Orthopaedic Innovation Centre

Winnipeg, Manitoba, R2K 2M9, Canada

Location status: Recruiting

Location contact

Bryan Flynn, MD

SUB_INVESTIGATOR

Colin Burnell, MD

SUB_INVESTIGATOR

David Hedden, MD

SUB_INVESTIGATOR

Eric Bohm, MD

SUB_INVESTIGATOR

Pakpoom Ruangsomboon, MD

SUB_INVESTIGATOR

Sarah Tran

CONTACT

[email protected]

204-926-1231

Thomas Turgeon, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals requiring primary THA for a severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia, AVN of the femoral head or acute traumatic fracture of the femoral head or neck.
  • Individuals who are able to speak, read and comprehend the informed patient consent document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information to DePuy Synthes.
  • Individuals who are willing and able to return for follow-up as specified by the study protocol.
  • Individuals who are a minimum age of 21 years at the time of consent.
  • Individuals who are willing and able to complete the Subject Hip Outcomes questionnaires as specified by the study protocol.

Exclusion criteria

  • Individuals who have active local or systemic infection.
  • Individuals who have loss of musculature, neuromuscular compromise or vascular compromise that would impact rehabilitation following surgery.
  • Individuals with poor bone quality, such as osteoporosis, where in the surgeon's opinion, there could be considerable migration of the prosthesis or require additional acetabular cup fixation using screws, or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the implant(s).
  • Individuals with Charcot's or Paget's disease.
  • Individuals who, in the judgement of the investigator, would not be a candidate for protocol allowable components to be used for their THA.
  • Women who are pregnant or lactating.
  • Individuals who have had a contralateral hip that was implanted less than 6 months prior to the time of consent into this study or individuals that expect to have a contralateral hip implanted in the following 6 months at the time of consent into this study.
  • Individuals that have amputations in either leg that would impact rehabilitation following surgery.
  • Individuals who are bedridden
  • Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
  • Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  • Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  • Individuals diagnosed and taking prescription medications to treat a muscular disorder that limits mobility due to sever stiffness and pain such as fibromyalgia or polymyalgia.
  • Subject has a medical condition with less than 2 years life expectancy.
  • Individual has a BMI >45 kg/m2.

Treatment and study plan

Emphasys Hip Solutions

Device

Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem

Primary outcomes

  1. Migration - Shell

    Time frame: 2 Years

    The mean vertical subsidence (Y translation, also known as superior shell migration) at 2 years as measured with RSA.

  2. Migration - Stem

    Time frame: 2 Years

    The mean vertical subsidence (Y translation, also known as inferior stem migration) at 2 years as measured with RSA.

Secondary outcomes

  1. Subsidence - Emphasys Shell

    Time frame: 6 months, 1 Year

    RSA measured subsidence of the Emphasys Shell at 6 months and 1 year and to compare it to historical Pinnacle Shell data

  2. Subsidence - Emphasys Stem

    Time frame: 6 months, 1 Year

    RSA measured subsidence of the Emphasys Stemat 6 months and 1 year

  3. Other RSA measurements - Emphasys Shell

    Time frame: 6 Weeks, 6 months, 1 year and 2 years

    Other RSA measurements of the Emphasys Shell (X and Z translations in mm, X, Y, and Z rotations in degrees, and maximal total point motion in mm) at all time points. These endpoints will be compared to historical Pinnacle Shell data.

  4. Other RSA measurements - Emphasys Stem

    Time frame: 6 Weeks, 6 months, 1 year and 2 years

    Other RSA measurements of the Emphasys Stem (X and Z translations in mm, X, Y, and Z rotations in degrees, and maximal total point motion in mm) at all time points. These endpoints will be compared to historical Pinnacle Shell data.

  5. Head Penetration (in mm)

    Time frame: 1 year and 2 years

    Linear head penetration (in mm) at 1 year and 2 years. This endpoint will be compared to historical Pinnacle data.

  6. HOOS Jr.

    Time frame: Pre-op, 6 weeks, 6 months, 1 year and 2 years

    Functional and health status will be measured with HOOS Jr. This is a patient-reported outcome measure for which scores range from 0 to 100; a score of 0 indicating total hip disability and 100 indicating optimal hip health.These endpoints will be compared to historical Pinnacle data.

  7. Harris Hip Score

    Time frame: Pre-op, 6 weeks, 6 months, 1 year and 2 years

    Functional score will be measured with Harris Hip Score. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points). These endpoints will be compared to historical Pinnacle data.

  8. Forgotten Joint Score (FJS-12)

    Time frame: Pre-op, 6 weeks, 6 months, 1 year and 2 years

    Functional and health status will be measured with the Forgotten Joint Score (FJS-12). The FJS total score range is 0-100, higher scores indicating the patient is able to forget the joint daily lower degree of joint awareness. These endpoints will be compared to historical Pinnacle data.

Study contacts

Contact information is provided by the study sponsor or research team.

Sarah Tran

CONTACT

[email protected]

204-926-1231

Shalini Hari Kumar

CONTACT

[email protected]

204-926-1232

Sponsors and collaborators

Lead sponsor

Canadian Radiostereometric Analysis Network

Other

Collaborators

  • Johnson & Johnson

Registry information

Official study title

Multi-Center, Non-Controlled, Prospective Radiostereometric Analysis of Emphasys Hip Solutions

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 18, 2023
Registry last updated
Dec 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.